RA Capital Management, L.P. has been steadily adding to its stake in Artiva Biotherapeutics, Inc. (ARTV), according to a new Form 4 filed with the SEC. The latest purchase, dated July 23, 2026, shows the firm buying 59,880 shares at $9.96 apiece, a transaction worth $596,404.80.
This is not an isolated trade. It’s the third open-market purchase from RA Capital in just three days, spanning July 21 through July 23, 2026, with the combined total across all three transactions reaching $2,583,314. When a single insider makes repeated purchases in a tight window like this, it’s typically flagged as a cluster buy, a pattern that tends to draw more attention than a single, one-off transaction because it suggests sustained conviction rather than a one-time decision.
What the Filing Shows
After this most recent purchase, RA Capital’s position in Artiva now stands at 17,242,483 shares, held indirectly through an entity structure such as a fund or affiliated vehicle rather than in the insider’s own name directly. RA Capital Management is a well-known life sciences-focused investment firm, and its involvement here is listed under an insider classification in the filing, reflecting its position as a significant holder of ARTV shares.
Artiva Biotherapeutics is a clinical-stage biotechnology company, and insider or major-holder purchases at this scale are notable for a company of its size. Spending north of $2.5 million across three days signals that RA Capital was actively acquiring shares at prices ranging in and around the $9.96 mark seen in the most recent trade, rather than making a single symbolic buy.
Academic research on insider trading patterns has found that clustered buying, meaning multiple insiders or the same insider purchasing shares repeatedly over a short period, has historically correlated with stronger subsequent stock performance compared to isolated purchases. That said, this correlation is a statistical observation from broader studies of insider trading data, not a prediction or endorsement tied to this specific filing. Every company and situation carries its own risks, and SEC disclosures like this one simply provide a transparent record of what insiders and major holders are doing with their own capital.
Readers tracking insider activity can view the underlying Form 4 filing directly through the SEC’s EDGAR system for the full transaction details and reporting history tied to RA Capital’s position in Artiva Biotherapeutics.
Source: original SEC Form 4 filing.